Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To compare relapse rates and quality of life inpatients with relapse remitting multiple sclerosis treated with natalizumab or interferon beta or glatiramer acetate

Trial Profile

To compare relapse rates and quality of life inpatients with relapse remitting multiple sclerosis treated with natalizumab or interferon beta or glatiramer acetate

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2018

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top